UnknownPhase 2NCT02588131
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
Studying Malignant peritoneal mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Italian Network for Tumor Biotherapy Foundation
- Principal Investigator
- Luana Calabro', MD, PhDMedical Oncology and Immunotherapy Division, Univeristy Hospital os Siena, Siena, Italy
- Intervention
- tremelimumab plus MEDI4736(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2018
Study locations (1)
- Medical Oncology and Immunotherapy Division, University Hospital of Siena, Siena, Italy
Collaborators
AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02588131 on ClinicalTrials.govOther trials for Malignant peritoneal mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07330271PTC-Guided Therapy for Peritoneal MesotheliomaBeijing Tsinghua Chang Gung Hospital
- RECRUITINGPHASE2NCT06543069Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGNCT06581549Immune Microenvironment and Gene Expression Profiling in MesotheliomaIstituto Oncologico Veneto IRCCS
- RECRUITINGPHASE2NCT06057935A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaMemorial Sloan Kettering Cancer Center